Press Release 2011 Free Papers Posters Main Sessions 88th Retinal Detatchment Course Uveitis Course EUROLAM Symposium French Israeli Association Kreissig Lecture ARVO Symposium EVICR.NET Amsterdam Retina Debate EUROVISIONNET Fluid Dynamics Symposium Instructional Courses Surgical Skills Training Courses

Main Sessions

THURSDAY 26 MAY

MAIN SESSION 1- 09.30 – 11.30
Research I: Vitreous Physiology and Disease

Chairperson: Z.Gregor UK, E. Stefansson ICELAND

J. Sebag  USA                                                   
Vitreous structure and function

E. Stefánsson ICELAND
Vitreous humour, viscosity and molecular transport

J. Bainbridge UK     
Oxygen metabolism following vitrectomy        

N. Holekamp USA 
Vitreous humor and oxygen consumption

M. Trese USA 
Effects of vitreolysis and posterior vitreous detachment

I. Krebs AUSTRIA 
Imaging and vitreous in AMD

S. Schmitz-Valckenberg GERMANY
Vitreoretinal interface abnornormalities in geographic atrophy

S. Schulze GERMANY
Vireoretinal adhesion in AMD

P. Bishop UK                                                 
Vitreous biochemistry

U. Schmidt-Erfurth AUSTRIA  
Cytokine and proteins in the vitreous in retinal disease: a proteomics analysis

 

MAIN SESSION 2 - 11.30 – 13.00
Research II: Drug Delivery to Retina

Chairperson: F. Holz GERMANY, B. Kuppermann USA, D. Wong UK

T. Nivagiolli USA
Novel technologies and future needs in retinal drug delivery

F. Behar-Cohen FRANCE
Non-viral gene delivery for protein delivery to the retina

A. Ohira JAPAN                    
Eye drops with dexamethasone for treatment of DME

W. Tao USA 
NT -501 encapsulated delivery system

B. Kuppermann USA 
Intravitreal steroid drug delivery system

E. Stefánsson ICELAND
Eye drops reach the retina and treat retinal disease

 

MAIN SESSION 3- 14.00 – 16.00
IMAGING

Chairperson: F. Holz GERMANY, S. Wolf SWITZERLAND

W. Drexler AUSTRIA
Recent developments in OCT technology

Z. Zweifel SWITZELAND
Enhanced-depth OCT-imaging for assessment of the choroid

M. Paques FRANCE
Imaging macular diseases using adaptive optics

U. Kellner GERMANY
Near-infrared fundus autoflourescence imaging in retinal diseases

S. Wolf SWITZERLAND
Autofluorescence imaging: relevance of different wavelegths

F. Holz GERMANY               
Imaging processing methods to analyze dry AMD progression

R. Silva PORTUGAL
Multimodal imaging to predict AMD progression

G. Staurenghi ITALY
Up-to-date use of ICG angiography

P. Charbel Issa GERMANY
Fundus fluorescence imaging in mice

 

MAIN SESSION 4 - 08.00 – 10.00
Surgical management of diabetic retinopathy

Chairperson: B. Aylward UK, C. Awh USA

P. Scanlon UK
Why do patients still require surgery for the late complications of Proliferative Diabetic Retinopathy?

W. Mieler USA
The Role of Surgery for DME

D. Callanan USA
Dexamethasone implants for DME

T. Nikolakopoulos GREECE
Treating Traction retinal detachment with small gauge vitrectomy

P. Ferrone USA
Tips for handling the "nightmare" diabetic vitrectomy.

S. Rizzo ITALY
Suprachoroidal infusion of drugs for subfoveal hard exudates

T. Hassan USA
Diabetic vitrectomy in an office setting

D. Wong UK
Preventing recurrent haemorrhage after vitrectomy

 

MAIN SESSION 5 - 14.00 – 16.00
EURETINA Innovation Award

Chairperson: E. Stefansson ICELAND

 

MAIN SESSION 6 - 16.00 – 18.00
UVEITIS

Chairperson: C. Pavesio UK, P. Lehoang FRANCE

P. LeHoang FRANCE, C. Pavesio UK
Introduction

M. Stanford UK
Behcet's Disease: New Trends & Current Management

M. Khairallah TUNISIA
Corticosteroid-induced Central Serous ChorioRetinopathy & Uveitis

C. Fardeau FRANCE
Fluorescein and Indocyanine Green Angiography findings in Susac's Syndrome

E. Graham UK
Retinal involvement in Pediatric Uveitides

M. Ramano ITALY
Intraocular Tamponade and Inflammation

C. Pavesio UK
Anti-Inflammatory Intraocular Therapy: Past, Present & Future

P. LeHoang FRANCE, C. Pavesio UK
Conclusion

 

SATURDAY 28 MAY

MAIN SESSION 7 - 08.00 – 10.00
Innovative Vitreoretinal Surgery

Chairperson: B. Aylward UK, D. Wong UK

L. da Cruz UK
Epiretinal implant

K. Bartz-schmidt GERMANY
Surgery for subretinal implant in patients with retinitis pigmentosa

F. Gekeler GERMANY
Subretinal implant - assessment of functional outcome

H. Tadandeh USA
The vitreous base in retinal detachment - to shave or not to shave

N. Lois UK
Is peeling of the ILM necessary for idiopathic macular hole - results of a randomised controlled study

Y. Le Mer FRANCE
Do we need dyes for ILM peeling? Results from a prospective clinical study

S. Kaushal USA
Surgical aspects of the LCA-RPE65 gene therapy trial

G. Willams USA
Encapsulated cilary neurotrophic factor (CNTF) - secreting cell implant for the treatment of geographic
atrophy associated with dry AMD

R. MacLaren USA
Choroidal surgery for AMD

S. Binder AUSTRIA
Intraoperative OCT - an update

 

MAIN SESSION 8 - 11.00 – 13.00
Anterior/Posterior Segment Surgery

Chairperson: B. Aylward UK, D. Wong UK

S. Prasad UK
Surgery for subluxed lens

H. Heimann GERMANY
Effect of cataract surgery on the posterior segment

S. Gotzairidis GREECE
Management of dislocated IOLs

M. de Smet SWITZERLAND
IOL implants and Vitrectomy

M. Wilkins UK
Implantable Miniature Telescope

P. Brazitikos GREECE
Management of the anterior segment in IOFB cases

J. Korobelnik FRANCE
Endophthalmitis after cataract surgery

S. Kaushal USA
Risk of retinal detachment and refractive surgery

F. Kuhn USA
Retained lens fragments after cataract surgery

 

MAIN SESSION 9 - 14.00 – 16.00
Diabetic Retinopathy

Chairperson: J. Cunha-Vaz PORTUGAL

T. Wong SINGAPORE
Epidemiology and systemic risk factors for DME

N. Bressler USA
Proposed Update of Classification of Diabetic Macular Edema

M. Ulbig GERMANY
Fundus Photography as a marker for progression to DME

R. Bernardes PORTUGAL
New approach for DME imaging using OCT

A Loewenstein ISRAEL
Update on steroids for DME

S. Bressler USA
Update on anti-VEGF treatment and laser for DME

F. Bandello ITALY
Combined treatment for diabetic macular edema

A. Kampik GERMANY
Vitrectomy in the management of macular edema

J. Cunha-Vaz PORTUGAL
Characterization of responders to different therapies

V. Chong UK
VEGF-Trap Da Vinci 12 month data

 

MAIN SESSION 10 - 16.00 – 18.00
Vascular Diseases

Chairperson: F. Bandello ITALY

F. Bandello ITALY
Classification and treatment options for diabetic macular edema

P. Massin FRANCE
Prognostic indicators in the treatment of diabetic macular edema

U. Schmidt-Erfurth AUSTRIA
Classification and treatment options for macular edema secondary to retinal vein occlusions

A. Augustin GERMANY
Prognostic indicators in the treatment of macular edema secondary to retinal vein occlusions

F. Holz GERMANY
6 month results of the VEGF-Trap CRVO Study (GALILEO)

M. Battaglia Parodi ITALY
Treatment of retinal arterial macroaneurysms

A. Gaudric FRANCE
Diagnosis and management of von Hippel-Lindau disease

U. Introini ITALY
Treatment of Vascularized PED

 

SUNDAY 29 MAY

MAIN SESSION 11 - 08.00 – 10.00
AMD I

Chairperson: F. Holz GERMANY, J. Korobelnik FRANCE, S. Wolf SWITZERLAND

C. Klaver THE NETHERLANDS
High risk genotypes of dry AMD

P. Luther UK
Role of Bruchs membrane in geographic atrophy

M. Rudolf GERMANY
Role of the RPE in geographic atrophy

U. Wolf-Schnurrbusch SWITZERLAND
Characterization of local retinal degeneration at the lesion boundary

F. Holz GERMANY
Quantification of disease progression: Autofluorescence imaging

U. Schmidt-Erfurth AUSTRIA
Quantification of disease progression: Polarization-sensitiveOCT

T. Hohman GERMANY
New Drug development for dry AMD

D. Martin USA
CATT results

 

MAIN SESSION 12 - 11.00 – 13.00
AMD II

Chairperson: G. Richard GERMANY

G. Richard GERMANY
Stem-cell Therapy in different AMD-Models

U. Schmidt-Erfurth AUSTRIA
OCT in the Diagnosis and Follow up of wet AMD

N. Bressler USA
Estimated cases of legal blindness avoided in the United States and in Europe with Ranibizumab for neovascular age-related Macular Degeneration

G. Soubrane FRANCE
Recent results from clinical trials in AMD – an update

G. Williams USA
Quality of life measurement in AMD

G. Kogame USA
Continuous monthly Anti-VEGF Therapy with Ranibizumab for active polypoidal choroidal Vasculopathy – long-term results

A Augustin GERMANY
Suprachoroidal drug delivery for the Treatment of advanced, exudative age-related Macular Degeneration

S. Wolf SWITZERLAND
Outcome of PRN-Regimen with Anti-VEGF-Treatment

P. Dugel USA
24 month outcomes of Epimacular Brachytherapy for the Treatment of CNV due to AMD

 

MAIN SESSION 13 - 11.00 – 13.00
Complications of High Myopia

Chairperson: S. Chang USA, A. Gaudric FRANCE

R. Spaide USA
Choroid in High Myopia

D. Gaucher FRANCE
Peripapillary changes in High Myopia

A. Gaudric FRANCE
Dome shaped macula

Y. Ikuno JAPAN
Surgical indication and results for Myopic foveoschisis

J. Garcia-Arumi SPAIN
Surgery for myopic macular hole without retinal detachment

S. Chang USA
Surgery for retinal detachment by macular hole

R. Tadayoni FRANCE
Vitrectomy in Highly myopic eyes: are there special tricks?

A. Pece ITALY
Results of antiVEGFs treatment for Myopic CNVs

EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy